chidamide + dexamethasone + ifosfamide + carboplatin + etoposide

This is a multi-agent chemotherapy regimen combining five drugs: - **Chidamide** is a selective inhibitor of class I and II histone deacetylases (HDACs), acting as an epigenetic modulator to inhibit tumor cell growth, induce apoptosis, and enhance immune-mediated tumor cell killing. It has been approved for relapsed or refractory peripheral T-cell lymphoma and investigated in other lymphomas[1][2]. - **Dexamethasone** is a synthetic glucocorticoid corticosteroid with anti-inflammatory and immunosuppressive properties. - **Ifosfamide**, **carboplatin**, and **etoposide** together form the ICE regimen, which is widely used as salvage chemotherapy for relapsed or refractory lymphomas and some solid tumors. Ifosfamide is an alkylating agent causing DNA crosslinking; carboplatin is a platinum-based compound that induces DNA damage; etoposide inhibits topoisomerase II, leading to DNA strand breaks[6][7][10]. This combination has been reported in case studies for aggressive hematologic malignancies such as hepatosplenic T-cell lymphoma (HSTCL), where chidamide was added to the ICE backbone to improve remission rates[2][9]. The rationale includes both direct cytotoxic effects from ICE plus epigenetic modulation by chidamide.